10 Best Immunology Stocks to Invest In

Published on December 13, 2022 at 10:05 am by Usman Kabir in Hedge Funds, News

In this article, we discuss the 10 best immunology stocks to invest in. If you want to read about some more immunology stocks, go directly to 5 Best Immunology Stocks to Invest In.

Immunology is the study of the immune system of higher organisms in relation to disease. To be more precise, immunology is the branch of biology that is concerned with the structure and function of the immune system. The subject is studied with the help of trials conducted based on laboratory techniques or immunoassays. If the immune system of a person is weak, then it could result in various diseases, such as autoimmunity, allergy and cancer. The global immunology market has exploded in the past few decades.

Vendors are deploying organic and inorganic growth strategies to compete in the market. According to a report by Fortune Business Insights, the global immunology market size is going to showcase exponential growth by reaching close to $159 billion in value by 2028. This implies a compound annual growth rate of more than 8% between 2021 and 2028. Globally, the eminent market players in the immunology market include Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV).

The growth of the immunology sector can be understood in context of a recent product. In 2021, Sandoz Canada introduced adalimumab. The drug provides high efficacy and efficiency in treating autoimmune diseases, including rheumatoid arthritis, adult Crohn’s disease, psoriatic arthritis, and adult uveitis. It has already received the required regulatory approvals across the world, indicating the enlarged market size for the product and the rising number of successful clinical trials being conducted globally.

In addition to this success story, there are several other genetic medicines and immunotherapies that are trending and proving successful at tackling genetic disorders and diseases. Investors are seeking exposure to advances in genomics and immunology and generating a significant portion of their revenue from related therapeutics and technologies. The prevalence of biosimilars has also helped the industry to reach new heights. Some estimates suggest that biosimilars will generate sales of over $3.4 billion in 2022. For example, biosimilars of Inflectra, developed by Pfizer, generated a whopping $671 million in sales this year.

The demand for allergists and immunologists is expected to go up, with an expected 72,500 new jobs filled by 2029. This represents an annual increase of more than 2% over the next few years. The COVID-19 outbreak has generated widespread economic distress and uncertainty, with many industries, markets, and businesses undergoing tremendous stress. However, the medical sciences community surpassed these challenging times and now has significant runways for growth in the immunology space.

Our Methodology

The companies that operate in the immunology sector were selected for the list. The business fundamentals and analyst ratings for the stocks are also discussed to provide readers with some additional insight for their investment decisions. Data from around 900 elite hedge funds tracked by Insider Monkey in the third quarter of 2022 was used to identify the number of hedge funds that hold stakes in each firm.

louis-reed-pwcKF7L4-no-unsplash

Best Immunology Stocks To Invest In

10. PureTech Health plc (NASDAQ:PRTC)

Number of Hedge Fund Holders: N/A

PureTech Health plc (NASDAQ:PRTC) is a clinical-stage biotherapeutics company that discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. On December 6, PureTech Health revealed that it would continue clinical trials for LYT-310, an oral cannabidiol prodrug that increases tolerability. The company plans to deliver the treatment orally in a capsule.

Just like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), PureTech Health plc (NASDAQ:PRTC) is one of the best immunology stocks to invest in according to elite investors.

9. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA)

Number of Hedge Fund Holders: 1

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. On November 30, ImmunoPrecise Antibodies announced that BioStrand BV, an AI discovery subsidiary of IPA, has entered into a research collaboration and license agreement with BrianCell Therapeutics Corp. The companies will focus on silico antibody discovery to generate relevant clinical molecules for potential development.

At the end of the third quarter of 2022, 1 hedge fund in the database of Insider Monkey held stakes worth $249,000 in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), compared to 2 in the previous quarter worth $472,000.

Among the hedge funds being tracked by Insider Monkey, Chicago-based firm Citadel Investment Group is a leading shareholder in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) with 263,300 shares worth more than $1 million.

8. Astria Therapeutics, Inc. (NASDAQ:ATXS)

Number of Hedge Fund Holders: 13

Astria Therapeutics, Inc. (NASDAQ:ATXS) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. On August 4, Astria Therapeutics revealed the initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, effective attack prevention for hereditary angioedema (HAE), with dosing once every three months or longer.

At the end of the third quarter of 2022, 13 hedge funds in the database of Insider Monkey held stakes worth $59.7 million in Teladoc Health, Inc. (NYSE: TDOC), compared to 9 in the previous quarter worth $10.45 million.

7. Genmab A/S (NASDAQ:GMAB)

Number of Hedge Fund Holders: 12

Genmab A/S (NASDAQ:GMAB) develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. On October 28, Genmab A/S announced that it has submitted a Biologics License Application to the US Food and Drug Administration for subcutaneous epcoritamab, an investigational bispecific antibody for the treatment of patients with relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy.

On November 14, William Blair analyst Matt Phipps initiated coverage of Genmab A/S (NASDAQ:GMAB) stock with a Market Perform rating without a price target, noting that the launch of the company’s partnered programs has significant longer-term potential, however, initial commercial indications are limited and additional time will be needed for its intriguing pipeline programs to take shape.

At the end of the third quarter of 2022, 12 hedge funds in the database of Insider Monkey held stakes worth $125 million in Genmab A/S (NASDAQ:GMAB), compared to 6 in the preceding quarter worth $96.4 million.

Among the hedge funds being tracked by Insider Monkey, Boston-based firm Arrowstreet Capital is a leading shareholder in Genmab A/S (NASDAQ:GMAB) with 1.4 million shares worth more than $47 million.

In its Q2 2021 investor letter, Artisan Partners, an asset management firm, highlighted a few stocks and Genmab A/S (NASDAQ:GMAB) was one of them. Here is what the fund said:

“Genmab A/S (NASDAQ:GMAB) is a creator and developer of human antibody products for the treatment of life-threatening and debilitating diseases. Shares have been volatile this year amid a binding arbitration with Johnson & Johnson to decide key aspects of royalty payments related to nextgeneration multiple myeloma drug, Darzalex FASPROTM. Last quarter, we indicated share weakness in February and early March seemed to overstate the potential negative outcome, especially relative to the additional growth opportunities within Genmab’s promising R&D pipeline. That potential was on display in Q2 when the company reported positive data for its bispecific antibody Epcoritamab, a new drug being developed with AbbVie to treat lymphoma. Bispecific antibodies are recombinant antibodies aimed at two biological targets simultaneously and are an important emerging technology area. The company expects to report further clinical trial updates later this year for another bispecific antibody it has developed with partner BioNTech. This new drug is expected to treat patients with metastatic or unresectable malignant solid tumors who are not candidates for standard therapy. We believe Genmab is establishing itself as one of the clear leaders in bispecifics, which increases our optimism about the long-term value of the company’s R&D platform.”

6. Takeda Pharmaceutical Company Limited (NYSE:TAK)

Number of Hedge Fund Holders: 12

Takeda Pharmaceutical Company Limited (NYSE:TAK) engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, the rest of Asia, and internationally. On November 22, Takeda Pharmaceutical Company said that it will help to treat patients suffering from hemophilia A more effectively. A major complication of this therapy is the development with a neutralizing immune reaction in 30% of the patients.

Among the hedge funds being tracked by Insider Monkey, New York-based firm Renaissance Technologies is a leading shareholder in Takeda Pharmaceutical Company Limited (NYSE:TAK) with 2.85 million shares worth more than $36.95 million.

At the end of the third quarter of 2022, 12 hedge funds in the database of Insider Monkey held stakes worth $104 million in Takeda Pharmaceutical Company Limited (NYSE:TAK), compared to 11 in the preceding quarter worth $83 million.

In addition to Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best immunology stocks to invest in according to elite investors.

Click to continue reading and see 5 Best Immunology Stocks to Invest In.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Published on May 1, 2024 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

Published on May 2, 2024 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up